Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9MW0813 vs Aflibercept in Diabetic Macular Edema
NCT05324774Phase 3Unknown
- Sponsor
- Mabwell
- Start
- Feb 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of 9MW0813 in diabetic macular edema (DME) (2 arms), sponsored by Mabwell. Primary endpoints: Change from Baseline in Best Corrected Visual Acuity at 8 weeks and Change from Baseline in Central Retinal Thickness at 8 weeks. Status: unknown.
02
Drugs
9MW0813
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05324774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05324774.